HOME >> BIOLOGY >> NEWS
Biological and chemical agents in terrorism examined at AAN Annual Meeting

HONOLULU, HI (March 31, 2003) - The neurological effects of bioterrorism and the history of biological warfare will be examined at the American Academy of Neurology 55th Annual Meeting taking place this week in Honolulu.

On Tuesday, April 1, "Biological Toxins in War and Terrorism - An Historical Overview" will be presented by Shrikant Mishra, MD, Department of Neurology, Keck School of Medicine, University of Southern California. Mishra will present the historical perspective of biological toxins used in warfare and global terrorism, from ancient to contemporary times. He will focus on such biological toxins as anthrax, smallpox, and botulinum toxin, their use in war and as terrorist weapons of mass destruction.

"The recent insurgence of national and international terrorism is a potential threat to the world as a whole," says Mishra. "Lessons learned from the past will be a guiding force for the future. Early recognition and elimination of these sources, and prompt treatment of exposure to biological toxins is essential for saving humanity."

A seminar on "Bioterrorism and Neurology" on Thursday, April 3 will focus on developing bioterrorism response plans for local hospitals and clinics, which would be expected to manage neurological complications of botulism, smallpox, anthrax and nerve gases. Faculty members for this program have expertise in both the clinical and basic science aspects of bioterrorism. Each of them has had experience as "preparedness" educators in their own practice settings: a U.S. Army hospital, a Veterans Affairs Medical Center, and an Indian Health Service Medical Center. This program is designed to prepare neurologists to be better educators on the neurological issues related to bioterrorism. Participants will learn the emergency medical management of patients exposed to biological warfare agents and nerve gases, and also learn about current basic research aimed to develop neuroprotective agents against the weapons of
'"/>

Contact: Marilee Reu
mreu@aan.com
651-695-2789
American Academy of Neurology
31-Mar-2003


Page: 1 2

Related biology news :

1. Biological oceanographers examine regime shifts in complex marine ecosystems
2. Biological computer diagnoses cancer and produces drug in a test tube
3. Biological cause of one form of blindness identified by SLU researchers
4. Biological trick reveals key step in melatonins regulation
5. Journal of Gerontology: Biological Sciences to offer forum
6. Biological clock more influenced by temperature than light
7. Systematics at a Crossroads: Biological and Philosophical Arguments
8. Biological Challenges to Humanity: Emerging and Re-emerging Pathogens
9. Biological evidence can persuade people to change unhealthy habits
10. Biological warfare: an emerging threat in the 21st century
11. Biological clock gene in bees found to have another function

Post Your Comments:
(Date:8/26/2015)... The report "Multi-Factor Authentication (MFA) Market ... (Travel & Immigration, Government, Banking, Defense, Commercial Security, Consumer ... published by MarketsandMarkets, Multi-Factor Authentication Market is expected to ... CAGR of 17.7% between 2015 and 2020. ... spread through 169 P ages and ...
(Date:8/24/2015)... CAPE TOWN, South Africa , August 24, 2015 /PRNewswire/ ... awarded Germany ,s largest biometrics manufacturer DERMALOG ... with the "2015 African Biometrics Company of the ... installation in Nigeria .   ... ) and http://www.presseportal.de/nr/8896 - On Thursday ...
(Date:8/20/2015)... Aug. 20, 2015 The wearable technology ... are active and healthy. However, wearable technology has ... environment to help improve diagnostic capabilities and therapeutic ... the Wearable Technologies Conference 2015 , where ... for wearables in healthcare.    "Over ...
Breaking Biology News(10 mins):Multi-Factor Authentication Market Worth 9.60 Billion USD by 2020 2Multi-Factor Authentication Market Worth 9.60 Billion USD by 2020 3Multi-Factor Authentication Market Worth 9.60 Billion USD by 2020 4Multi-Factor Authentication Market Worth 9.60 Billion USD by 2020 5Frost & Sullivan Honors DERMALOG with Biometrics Prize for Achievements in Africa 2Frost & Sullivan Honors DERMALOG with Biometrics Prize for Achievements in Africa 3Leaf Healthcare Releases Video from Wearable Technology Conference on New Applications for Wearables in the Hospital Environment 2Leaf Healthcare Releases Video from Wearable Technology Conference on New Applications for Wearables in the Hospital Environment 3
(Date:8/26/2015)... - iCo Therapeutics ("iCo" or "the Company") (TSX-V: ICO) ... quarter ended June 30, 2015. Amounts, unless specified ... under International Financial Reporting Standards ("IFRS"). ... Oral Amp B program, rapidly advancing towards the ... Rae , President & CEO of iCo Therapeutics. "We ...
(Date:8/26/2015)... ... August 26, 2015 , ... Lee Biosolutions, a global ... and manufacture of highly valued cardiac markers used in early detection of heart ... protein chemistry has led to the development and commercialization of important cardiac biomarkers ...
(Date:8/26/2015)... , Aug. 26, 2015  Platform therapeutic company ... has received a $1.5M Phase II SBIR grant ... further develop its therapeutic agent to reduce arteriovenous ... in end stage renal disease (ESRD) patients undergoing ... Institute of Diabetes and Digestive and Kidney Diseases ...
(Date:8/26/2015)... and BEIJING , August 26, 2015 ... Scene with Impressive Acheivements  DiaCardio wins 1 st ... The competition, led in Israel ... featured 21 startups from countries including the US, China ... and Latin America .  Impressive ...
Breaking Biology Technology:iCo Therapeutics Announces Second Quarter 2015 Financial Results 2iCo Therapeutics Announces Second Quarter 2015 Financial Results 3Lee Biosolutions Announces Increased Investment in the Development and Manufacturing of Biomarkers Used in Early Detection Of Heart Disease 2Symic Biomedical Awarded $1.5MM NIH Phase II SBIR Grant to Develop its Proteoglycan Mimetic Therapeutics to Reduce Vascular Access Failures in ESRD 2Symic Biomedical Awarded $1.5MM NIH Phase II SBIR Grant to Develop its Proteoglycan Mimetic Therapeutics to Reduce Vascular Access Failures in ESRD 3Israeli Startup Takes First Place at Shengjing Global Innovation Awards 2015 2Israeli Startup Takes First Place at Shengjing Global Innovation Awards 2015 3Israeli Startup Takes First Place at Shengjing Global Innovation Awards 2015 4Israeli Startup Takes First Place at Shengjing Global Innovation Awards 2015 5Israeli Startup Takes First Place at Shengjing Global Innovation Awards 2015 6
Cached News: